Display options
Cite
Motie M, Evangelista LS, Horwich T, et al. Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Exp Ther Med. 2014;8(1):181-186doi: 10.3892/etm.2014.1673.
Motie, M., Evangelista, L. S., Horwich, T., Lombardo, D., Zaldivar, F., Hamilton, M., & Fonarow, G. C. (2014). Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Experimental and therapeutic medicine, 8(1), 181-186. https://doi.org/10.3892/etm.2014.1673
Motie, Marjan, et al. "Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome." Experimental and therapeutic medicine vol. 8,1 (2014): 181-186. doi: https://doi.org/10.3892/etm.2014.1673
Motie M, Evangelista LS, Horwich T, Lombardo D, Zaldivar F, Hamilton M, Fonarow GC. Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Exp Ther Med. 2014 Jul;8(1):181-186. doi: 10.3892/etm.2014.1673. Epub 2014 Apr 08. PMID: 24944619; PMCID: PMC4061200.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2014 Jul;8(1):181-186. doi: 10.3892/etm.2014.1673. Epub 2014 Apr 08.

Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome.

Experimental and therapeutic medicine

Marjan Motie, Lorraine S Evangelista, Tamara Horwich, Dawn Lombardo, Frank Zaldivar, Michele Hamilton, Gregg C Fonarow

Affiliations

  1. Program of Nursing Science, University of California Irvine, Irvine, CA 92697, CA, USA.
  2. Division of Cardiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles 90095, CA, USA.
  3. Division of Cardiology, Department of Medicine, University of California Irvine Medical Center, Orange 92868, CA, USA.
  4. Institute for Clinical and Translational Science, University of California Irvine Medical Center, Orange 92868, CA, USA.
  5. Cedars-Sinai Heart Institute, Los Angeles 90048, CA, USA.

PMID: 24944619 PMCID: PMC4061200 DOI: 10.3892/etm.2014.1673

Abstract

Obesity, type 2 diabetes mellitus (DM) and metabolic syndrome (MS) are common in patients with heart failure (HF). Studies investigating the association between known biomarkers and adiposity in patient populations are limited. The aim of the present study was to investigate the association between C-reactive protein (CRP) and leptin with adiposity in a sub-group of overweight/obese patients with HF, DM and/or MS. A total of 36 patients (mean age, 56.72±9.78 years; ranging between 27 and 76 years of age; 80.6% male; 52.8% Caucasian) were enrolled and their height, weight, waist circumference and body composition (e.g. percentage body fat and lean mass), as well as the levels of CRP and leptin, were assessed. The results demonstrated that there was a significant association between CRP and leptin, CRP and body mass index (BMI) and gender and percentage body fat (P<0.05, for all associations). Analysis of leptin and CRP levels revealed that patients in the highest BMI quartile (BMI, 40.3-61.2) had higher CRP levels (4.83 μg/ml vs. 3.03 μg/ml; P=0.033) and higher leptin levels (44.97 ng/ml vs. 24.64 ng/ml; P=0.042) compared with patients in the lower BMI quartile (BMI, 28.6-32.4). In conclusion, among obese patients with HF, DM and/or MS, an association between CRP and leptin was identified, providing further evidence that metabolic and inflammatory mechanisms are involved in these diseases. Future investigation to assess the potential impact of inflammation and adiposity, and the role of dietary interventions and weight loss on clinical outcomes in this population of chronically ill patients is warranted.

Keywords: C-reactive protein; biomarkers; heart failure; leptin; obesity

References

  1. Obes Res. 2005 Aug;13(8):1476-84 - PubMed
  2. J Am Coll Cardiol. 2001 Sep;38(3):789-95 - PubMed
  3. Am Heart J. 2013 Jul;166(1):45-51 - PubMed
  4. Nat Med. 2006 Apr;12(4):425-32 - PubMed
  5. Hepatology. 1990 Nov;12(5):1179-86 - PubMed
  6. Metabolism. 2003 Sep;52(9):1113-6 - PubMed
  7. J Card Fail. 2002 Aug;8(4):206-15 - PubMed
  8. Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972-8 - PubMed
  9. J Am Coll Cardiol. 2005 Aug 2;46(3):464-9 - PubMed
  10. Circulation. 1999 Jan 19;99(2):237-42 - PubMed
  11. J Card Fail. 2003 Feb;9(1):29-35 - PubMed
  12. Contemp Clin Trials. 2013 Nov;36(2):371-81 - PubMed
  13. Circulation. 2004 Jul 27;110(4):380-5 - PubMed
  14. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1121-7 - PubMed
  15. Circulation. 2004 May 11;109(18):2181-5 - PubMed
  16. Cardiovasc Diabetol. 2012 Apr 25;11:40 - PubMed
  17. Eur Heart J. 2001 Aug;22(15):1318-27 - PubMed
  18. N Engl J Med. 2004 Dec 16;351(25):2599-610 - PubMed
  19. Trends Endocrinol Metab. 2010 Nov;21(11):643-51 - PubMed
  20. Nat Clin Pract Endocrinol Metab. 2006 Jun;2(6):318-27 - PubMed
  21. Science. 1995 Jul 28;269(5223):543-6 - PubMed
  22. Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):e302-7 - PubMed
  23. J Clin Endocrinol Metab. 2009 Sep;94(9):3251-8 - PubMed
  24. Circulation. 2003 Jan 28;107(3):391-7 - PubMed
  25. J Gastrointest Surg. 2009 Jul;13(7):1205-12 - PubMed
  26. J Intern Med. 1999 Oct;246(4):409-18 - PubMed
  27. Curr Pharm Des. 2014;20(4):646-51 - PubMed
  28. Circulation. 2001 Dec 18;104(25):3052-6 - PubMed
  29. Circulation. 2005 Jul 5;112(1):25-31 - PubMed
  30. Lancet. 2003 Mar 29;361(9363):1077-83 - PubMed
  31. J Clin Endocrinol Metab. 2007 Dec;92(12):4753-8 - PubMed
  32. Am J Cardiol. 2007 Jul 15;100(2):234-9 - PubMed
  33. Curr Pharm Des. 2014;20(4):609-15 - PubMed
  34. Diabetes Res Clin Pract. 2007 Jan;75(1):2-6 - PubMed
  35. JAMA. 1999 Dec 8;282(22):2131-5 - PubMed
  36. Am J Cardiol. 2005 Oct 1;96(7):991-5 - PubMed

Publication Types

Grant support